Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 16;27(7):1997–2010. doi: 10.1158/1078-0432.CCR-20-3322

Fig. 4: Growth suppression of ERCC2 and ERCC3 mutant tumors in response to irofulven and discovery of pathways de-regulated in ERCC3 mutant tumors.

Fig. 4:

(A) Patient-derived xenografts from an individual with small cell lung cancer harboring a truncating mutation in ERCC2; p.E85* (c.253G>T), show substantial growth suppression in response to irofulven. Tumors initially respond to treatment with cisplatin as well, but here tumors ceased to respond after the second treatment cycle (B) Irofulven mediates strongly increased and sustained growth suppression in CRISPR engineered ERCC3 heterozygous mutant xenografts.